However, given that URI1 plays critical roles in HCC, as previously reported, and that HBx and c-MYC are well-known oncogenic factors, this transcriptional regulatory mechanism may be a potential therapeutic target for HCC-B. The gene discussed is MYC; the disease is hepatocellular carcinoma.